214 related articles for article (PubMed ID: 33982509)
1. [Thoughts on post-marketing evaluation of classical Chinese patent medicines based on clinical value].
Song Z; Wang ZF; Wu Y; Xie YM; Yang YF; Xu Y
Zhongguo Zhong Yao Za Zhi; 2021 Apr; 46(8):1988-1993. PubMed ID: 33982509
[TBL] [Abstract][Full Text] [Related]
2. [Exploration and practice of post-marketing survival benefit evaluation of Chinese patent medicine for cancer].
Xu BW; Wu JY; Li J; Zhang Y; Cao LC; Zhang XX; Gao RK
Zhongguo Zhong Yao Za Zhi; 2021 Apr; 46(8):1980-1987. PubMed ID: 33982508
[TBL] [Abstract][Full Text] [Related]
3. [Key points of post-marketing evaluation of classic traditional Chinese medicine prescriptions based on combination of disease and syndrome].
Wang XL; Zhu MJ; Wang JR; Li B; Yu R; Peng GC; Zhao QF; Wang YX
Zhongguo Zhong Yao Za Zhi; 2021 Apr; 46(8):2004-2009. PubMed ID: 33982512
[TBL] [Abstract][Full Text] [Related]
4. [Guidelines for post-marketing research on clinical effectiveness of Chinese patent medicines].
Wang ZF; Xie YM; Tang JY; Zhang JH; Sun X; Yang ZQ
Zhongguo Zhong Yao Za Zhi; 2024 Feb; 49(3):842-848. PubMed ID: 38621888
[TBL] [Abstract][Full Text] [Related]
5. [Guidelines for economic evaluation of post-marketing Chinese patent medicine].
Shi LW; Xie YM; Nie XY; Han S; Tian X; Wang ZF
Zhongguo Zhong Yao Za Zhi; 2024 Feb; 49(4):1129-1136. PubMed ID: 38621920
[TBL] [Abstract][Full Text] [Related]
6. [Improvement of high-quality evaluation criteria of Chinese patent medicines based on whole process control].
Liu Y; Guo C; Zhang J; Xu QX; Zhao AY; Lao YZ; Su JM; Wang ZG; Liu YZ; Chen S; Liu A
Zhongguo Zhong Yao Za Zhi; 2023 Mar; 48(6):1700-1704. PubMed ID: 37005858
[TBL] [Abstract][Full Text] [Related]
7. [Technical specification for Instructions for Clinical Application of Chinese Patent Medicines in China Association of Chinese Medicine].
Zhang XM; Sa RN; Zhang B; Zhang D; Lyu JT; Duan XJ; Lin ZJ; Guo YB
Zhongguo Zhong Yao Za Zhi; 2021 Sep; 46(17):4563-4568. PubMed ID: 34581062
[TBL] [Abstract][Full Text] [Related]
8. [Evidence map analysis of randomized controlled trial of commonly used Chinese patent medicines in treatment of type 2 diabetes mellitus in recent five years].
Jiang JJ; Jing YY; Li YY; Yang YN; Liao X; Xie YM
Zhongguo Zhong Yao Za Zhi; 2024 Feb; 49(4):1102-1112. PubMed ID: 38621917
[TBL] [Abstract][Full Text] [Related]
9. [Study on precise mechanism of Chinese patent medicine from perspective of activating data].
Wang LX; Xie YM
Zhongguo Zhong Yao Za Zhi; 2020 Jul; 45(14):3331-3335. PubMed ID: 32726047
[TBL] [Abstract][Full Text] [Related]
10. [Application of objective performance criteria in post-marketing evaluation schemes of traditional Chinese medicine].
Zhang C; Yu MK; Tang JP; Huo YQ; Fei YT; Wang ZF; Xu Q; Xie YM
Zhongguo Zhong Yao Za Zhi; 2021 Apr; 46(8):1999-2003. PubMed ID: 33982511
[TBL] [Abstract][Full Text] [Related]
11. The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence.
Zhang D; Zhang B; Lv JT; Sa RN; Zhang XM; Lin ZJ
Pharmacol Res; 2020 Jul; 157():104882. PubMed ID: 32380051
[TBL] [Abstract][Full Text] [Related]
12. CPMCP: a database of Chinese patent medicine and compound prescription.
Sun C; Huang J; Tang R; Li M; Yuan H; Wang Y; Wei JM; Liu J
Database (Oxford); 2022 Aug; 2022():. PubMed ID: 36006844
[TBL] [Abstract][Full Text] [Related]
13. Chinese patent medicine as a complementary and alternative therapy for type 2 diabetes mellitus: A scoping review.
Zheng HZ; Chang TY; Peng B; Ma SQ; Zhong Z; Cao JZ; Yao L; Li MY; Wang HF; Liao X
Complement Ther Med; 2024 Mar; 80():103014. PubMed ID: 38184284
[TBL] [Abstract][Full Text] [Related]
14. [Explore method about post-marketing safety re-evaluation of Chinese patent medicines based on HIS database in real world].
Yang W; Xie Y; Zhuang Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2779-82. PubMed ID: 22292363
[TBL] [Abstract][Full Text] [Related]
15. [Theoretical thinking on guiding research and development of new drugs of traditional Chinese medicine].
Yang ZQ; Tang HM; Tang YQ; DU YP; Yuan WA; Li B; Zou C; Tang JY; Gao R; Hu SY; Zhang L
Zhongguo Zhong Yao Za Zhi; 2021 Apr; 46(7):1686-1690. PubMed ID: 33982469
[TBL] [Abstract][Full Text] [Related]
16. [Systematic review on methodology of randomized controlled trials of post-marketing Chinese patent drugs for treatment of type 2 diabetes].
Ma LX; Wang YY; Li XX; Liu JP
Zhong Xi Yi Jie He Xue Bao; 2012 Mar; 10(3):279-92. PubMed ID: 22409917
[TBL] [Abstract][Full Text] [Related]
17. [Expert consensus on core indicators for lifecycle value assessment of Chinese patent medicine].
Yu YN; Liu J; Li B; Dang HX
Zhongguo Zhong Yao Za Zhi; 2023 Oct; 48(19):5389-5396. PubMed ID: 38114128
[TBL] [Abstract][Full Text] [Related]
18. Chinese patent medicines for coronary microvascular disease: clinical evidence and potential mechanisms.
Yang Z; Liu Y; Song Z; Fan Y; Lin S; Ge Z; Feng S; Liu Y; Bi Y; Wang Y; Wang X; Mao J
Int J Med Sci; 2023; 20(8):1024-1037. PubMed ID: 37484810
[TBL] [Abstract][Full Text] [Related]
19. Clinical application of oral Chinese Patent Medicines in ophthalmology: a scoping review protocol.
Xu K; Liao X; Liang L; Li Y; Huang Z; Li X; Zhou W; Zuo Q
BMJ Open; 2022 Jun; 12(6):e059571. PubMed ID: 35725246
[TBL] [Abstract][Full Text] [Related]
20. [Report standards for clinical comprehensive evaluation of Chinese patent medicine].
Zhang Q; Wang ZF; Xie YM; Li YY; Wang LX; Liu H; Geng HJ; Cui X; Liu FM; Sun CQ; Wei RL; Zhang LD
Zhongguo Zhong Yao Za Zhi; 2021 Dec; 46(23):6062-6067. PubMed ID: 34951233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
